SS-31 (Elamipretide): The Mitochondria-Targeted Peptide at the Frontier of Longevity Research

Of all the compounds attracting serious attention in longevity research, SS-31 may be the one with the most compelling mechanistic story. Where many peptides work upstream — influencing hormones, signalling pathways, or receptor activity — SS-31 operates at the most fundamental level of cellular biology: the inner mitochondrial membrane.

Understanding SS-31 requires a brief detour into mitochondrial biology. But the payoff is significant: once the mechanism is clear, the breadth of conditions that mitochondrial dysfunction underlies — and that SS-31 research targets — becomes immediately apparent.

What Is SS-31?

SS-31, also known as elamipretide or by its research designation MTP-131, is a synthetic tetrapeptide. Its amino acid sequence is: D-Arg-2′,6′-dimethylTyr-Lys-Phe-NH₂.

This small four-amino-acid structure is specifically designed to:

1. Cross the cell membrane without requiring a transporter
2. Concentrate selectively at the inner mitochondrial membrane (IMM)
3. Bind cardiolipin — a phospholipid unique to the IMM — with high affinity

The result is a peptide that goes precisely where mitochondrial dysfunction originates.

The Cardiolipin Connection: Why the IMM Matters

Cardiolipin is a phospholipid found almost exclusively in the inner mitochondrial membrane. It is structurally essential to:

• Cristae architecture — the folded internal structure of mitochondria that maximises surface area for energy production
• Electron transport chain (ETC) stability — cardiolipin physically anchors and organises the protein complexes that generate ATP
• Cytochrome c retention — cardiolipin binds cytochrome c, keeping it localised at the ETC rather than triggering apoptotic cascades

In healthy, young cells, cardiolipin is abundant and intact. With age — and under conditions of oxidative stress, metabolic dysfunction, or ischaemia — cardiolipin becomes peroxidised: oxidatively damaged by reactive oxygen species (ROS). This damage:

• Destabilises cristae structure
• Reduces ETC efficiency and ATP output
• Releases cytochrome c, initiating cell death pathways
• Creates a self-amplifying cycle of mitochondrial dysfunction

SS-31 interrupts this cycle directly. By binding to cardiolipin, it:

• Stabilises cardiolipin against peroxidation — scavenging the electrons that would otherwise oxidise it
• Restores cristae architecture — allowing ETC complexes to reassemble into functional supercomplexes
• Reduces mitochondrial ROS production — breaking the oxidative stress feedback loop
• Preserves ATP synthesis — restoring cellular energy to more youthful parameters

This mechanism makes SS-31 uniquely relevant to any condition driven by mitochondrial dysfunction — which, as the research below shows, is a very long list.

Key Research Findings

Cardiac Function and Heart Failure

Some of the most striking published research on SS-31 comes from cardiac biology. Mitochondria make up approximately 30% of cardiac cell volume — the heart is the body's most mitochondria-dense organ, and the most vulnerable to mitochondrial decline.

In a landmark study published in Science Translational Medicine (Siegel et al., 2013), 4-week SS-31 treatment in aged rats:

• Restored cardiac structure to levels comparable to young animals
• Increased maximum cardiac workload capacity by ~38%
• Normalised mitochondrial cristae ultrastructure

These results were achieved without exercise or caloric restriction — through mitochondrial rescue alone.

Human clinical trials have followed. The PROGRESS-HF trial examined SS-31 (elamipretide) in heart failure with preserved ejection fraction (HFpEF) — a condition with no approved disease-modifying therapy. Results showed significant improvement in six-minute walk distance and reduction in left ventricular end-systolic volume index.

Age-Related Skeletal Muscle Decline (Sarcopenia)

Sarcopenia — the progressive loss of muscle mass and function with age — is now understood to be substantially driven by mitochondrial dysfunction in muscle fibres. Aged skeletal muscle shows:

• Reduced mitochondrial biogenesis
• Increased mitochondrial fission (fragmentation)
• Elevated ROS and oxidative damage
• Decreased ATP production per unit of oxygen consumed

SS-31 research in aged animal models has consistently reversed these parameters. In one study, 8 weeks of SS-31 treatment in aged mice:

• Restored muscle mitochondrial function to levels indistinguishable from young animals
• Increased treadmill running capacity by ~41%
• Reduced markers of oxidative stress in muscle tissue
• Improved mitochondrial ultrastructure to youthful morphology

For researchers interested in healthspan and physical performance, this is among the most relevant SS-31 data.

Kidney Protection and Renal Function

Renal tubular cells are among the most energetically demanding cells in the body and are therefore exquisitely sensitive to mitochondrial dysfunction. SS-31 has shown significant nephroprotective effects across multiple models:

• Ischaemia-reperfusion injury: Marked reduction in tubular necrosis and preserved GFR in rodent models when SS-31 was administered peri-ischaemia
• Contrast-induced nephropathy: Significant reduction in creatinine elevation and tubular injury in animal models
• Diabetic nephropathy: Reduced podocyte injury and glomerular filtration impairment in diabetic mouse models

This research arm has generated the most clinical interest, with elamipretide advancing to Phase 2 trials for Barth syndrome — a rare mitochondrial disorder affecting cardiac and skeletal muscle.

Neurological and Cognitive Applications

The brain is the second most mitochondria-dense organ in the body. Neurological diseases from Alzheimer's to Parkinson's to traumatic brain injury all involve mitochondrial dysfunction as a key pathological feature.

SS-31 research in neuroscience contexts has shown:

• Preservation of synaptic mitochondria under oxidative challenge
• Reduced amyloid-beta-induced mitochondrial fragmentation
• Improved spatial memory and cognitive performance in aged rodent models
• Protection against MPTP-induced dopaminergic neuron loss (a Parkinson's model)

While human neurological trials are at early stage, the mechanistic rationale is among the strongest of any longevity-oriented peptide being investigated.

Dosage Protocols in Research Settings

SS-31 is typically administered subcutaneously. Clinical trial dosages have varied by indication:

Important note on dosing: Animal-to-human dose translation requires careful consideration of allometric scaling. The rodent doses cited above are not directly applicable to human research protocols. All protocol design should be conducted with reference to published human trial data and ideally with informed guidance.

BioPepTech offers free consultation to discuss SS-31 protocol design in detail — including appropriate dosage ranges informed by clinical trial data, cycling approaches, and monitoring markers.

SS-31 in the Longevity Stack Context

SS-31 is rarely the only compound relevant to a longevity-oriented research protocol. The mitochondrial axis it targets has significant interactions with other compounds:

SS-31 + NAD+: NAD+ is a critical cofactor in the electron transport chain. As NAD+ levels decline with age, ETC efficiency falls — a problem that SS-31's structural stabilisation of ETC supercomplexes directly addresses. The two compounds work on complementary aspects of the same system. See our NAD+ mitochondrial research overview.

SS-31 + MOTS-c: MOTS-c is a mitochondrial-encoded peptide that promotes mitochondrial biogenesis — the creation of new mitochondria. SS-31 preserves the function of existing mitochondria. Together, they address both quality and quantity of mitochondrial capacity. See our MOTS-c metabolic health article.

SS-31 + BPC-157: For researchers focused on tissue repair and systemic recovery, BPC-157's angiogenic and anti-inflammatory properties complement SS-31's cellular energy restoration. Injured tissues require both improved blood supply and restored cellular energy metabolism to heal optimally.

Quality Considerations: Why SS-31 Sourcing Matters

SS-31's tetrapeptide structure makes it relatively straightforward to synthesise — which also means the market includes sources with variable purity standards. Given that the compound is administered subcutaneously, purity is not a cosmetic concern. Endotoxin contamination, incorrect sequence assembly, or inadequate sterility can cause injection site reactions, systemic inflammation, or simply an inactive compound.

BioPepTech's SS-31 is synthesised at pharmaceutical-grade facilities and verified by independent third-party certificate of analysis for:

• Sequence integrity (HPLC verification)
• Purity ≥99%
• Endotoxin levels
• Sterility (lyophilised form)

We make the full CoA available with every order. If you'd like to understand how to read and evaluate a peptide CoA, see our Certificate of Analysis guide.

Why SS-31 Represents a Different Class of Longevity Research

Most longevity interventions — exercise, caloric restriction, rapamycin, senolytics — work by influencing the signals that tell cells to behave younger. SS-31 is different. It addresses the physical deterioration of the cellular machinery responsible for energy production.

In this sense, SS-31 research is less about slowing a signal and more about restoring a structure. The distinction matters because structural restoration, in animal models, has produced outcomes that pure signalling interventions have not achieved — including the restoration of cardiac and skeletal muscle function to genuinely youthful parameters.

Whether that translates fully to humans remains the active question in ongoing clinical research. But the mechanistic rationale is among the strongest in the longevity peptide space, and the safety profile in clinical trials to date has been favourable.

View our SS-31 (CHARGE) product page or book your free consultation to discuss whether SS-31 belongs in your protocol.